The successful delivery of CGTs hinges on the development of scalable and resilient supply chains that can meet difficult logistical requirements and temperature controls.
Significant breakthroughs in CNS biology, coupled with innovative neuroscience technologies and a more supportive regulatory landscape, have fuelled increased investment and pharmaceutical interest
